IPX-461, also known as rivoglitazone, is an investigational drug that was under development for the treatment of type 2 diabetes mellitus. This comprehensive review aims to summarize the current state of knowledge on IPX-461, including its mechanism of action, pharmacokinetics, efficacy, safety, and regulatory status. The review also discusses the potential benefits and limitations of IPX-461 as a therapeutic agent for type 2 diabetes.
IPX-461 was granted Fast Track designation by the US Food and Drug Administration (FDA) in 2009. However, in 2016, the FDA issued a Complete Response Letter to the New Drug Application (NDA) for IPX-461, citing concerns regarding the drug's efficacy and safety. The FDA also requested additional clinical trials to further evaluate the benefits and risks of IPX-461.
Several clinical trials have evaluated the efficacy of IPX-461 in patients with type 2 diabetes. In a phase II study, IPX-461 demonstrated significant improvements in glycemic control, including reductions in hemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels. In a phase III study, IPX-461 showed comparable efficacy to pioglitazone, a marketed TZD, in improving glycemic control and lipid profiles.
